Can psilocybin promote neuroplasticity in the human brain?

What is neuroplasticity and why does it matter for psilocybin's effects?

Neuroplasticity is the brain's ability to reorganize itself by forming new neural connections throughout life. It's the biological basis of learning, memory, and recovery from injury or mental illness. When researchers say psilocybin promotes neuroplasticity, they mean it helps the brain rewire—growing new synapses, strengthening existing ones, and making brain networks more flexible. This is important because many mental health conditions, like depression and PTSD, are linked to rigid, stuck patterns of brain activity and connectivity.

A 2024 study using precision functional mapping (tracking individual brains with ~18 MRI scans each) found that a single 25 mg dose of psilocybin massively disrupted functional connectivity across the cortex and subcortex—more than three times the change caused by methylphenidate (Ritalin) [3]. These changes were driven by brain desynchronization, essentially dissolving the usual boundaries between brain networks. The default mode network, which is involved in our sense of self and rumination, was most affected. Crucially, some of these changes persisted for weeks, particularly a lasting decrease in connectivity between the anterior hippocampus and the default mode network [3]. The researchers describe this as a 'proplasticity' correlate of psilocybin's therapeutic effects.

What direct evidence shows psilocybin increases neuroplasticity in humans?

The strongest direct evidence comes from a 2023 double-blind, placebo-controlled study in 19 people with major depressive disorder [1]. Participants received placebo first, then psilocybin (0.3 mg/kg) four weeks later. Researchers measured EEG theta power (4-8 Hz brain waves) as an index of long-term potentiation—a cellular mechanism of learning and memory. Two weeks after psilocybin, theta power doubled in amplitude compared to placebo [1]. This is a direct measure of sustained brain change. Even more telling, the increase in theta power correlated with improvements in depression symptoms on the GRID-HAM-D-17 scale [1]. This suggests the neuroplastic changes are not just a side effect but are linked to clinical benefit.

Another 2025 study used PET imaging to measure synaptic density in 15 healthy participants one week after psilocybin [5]. They found that participants who had the psychedelic experience in a therapeutic-like room (vs. an MRI scanner) showed greater increases in synaptic density in the frontal cortex and hippocampus—key regions for mood and cognition [5]. This is important because it shows that the context ("set and setting") can modulate the degree of neuroplastic change. The study measured the synaptic vesicle glycoprotein 2A (SV2A), a direct marker of synapse density [5].

How does psilocybin trigger neuroplasticity at the cellular level?

Psilocybin's neuroplastic effects start when its active metabolite, psilocin, activates serotonin 2A receptors (5-HT2ARs) on brain cells. A 2026 study using in vivo imaging in mice showed that psilocybin promotes the formation of new synapses while accelerating the elimination of old ones—essentially remodeling the brain's wiring [6]. The researchers found that 5-HT2ARs on layer 5 pyramidal neurons in the cortex are necessary and sufficient for this neuroplasticity, but surprisingly, these same receptors are not required for the hallucinogenic effects [6]. This means it may be possible to separate the therapeutic plasticity from the psychedelic experience.

A 2025 study found that psilocybin and psilocin also act on microglia—the brain's immune cells—to reduce inflammation and increase brain-derived neurotrophic factor (BDNF), a protein that supports neuron growth and survival [8]. This effect involved multiple receptors: 5-HT2A, 5-HT2B, 5-HT7, and the TrkB receptor for BDNF, as well as the aryl hydrocarbon receptor (AhR) for psilocin's effects on BDNF [8]. This dual action—directly promoting synapse growth and reducing inflammatory inhibition of plasticity—may explain why psilocybin's effects are so robust. A 2021 systematic review of 20 studies (16 preclinical, 4 clinical) concluded that a single dose of a psychedelic produces rapid changes in plasticity-related genes and proteins (like BDNF), leading to increased dendritic complexity that outlasts the acute drug effects [7].

What does this mean for treating mental health conditions?

The link between psilocybin-induced neuroplasticity and symptom improvement is most clearly shown in depression. In the 2023 EEG study, the doubling of theta power at 2 weeks correlated with reduced depression scores [1]. A 2023 mouse study found that psilocybin facilitated fear extinction—a key process in exposure therapy for PTSD—by rescuing hippocampal dendritic complexity, spine density, and BDNF levels that were reduced by fear conditioning [4]. The effects were rapid (seen at 24 hours) and sustained (still present at day 7) [4]. This suggests psilocybin could be a useful adjunct to psychotherapy for PTSD and other disorders involving failure of fear extinction.

However, the evidence is not universally positive. A 2025 study in a mouse model of obsessive-compulsive disorder (OCD) found that psilocybin did not improve anxiety-like behaviors in juvenile mice, even though it increased synaptic proteins (GAP43, synaptophysin, SV2A) in adult mice [2]. This highlights that neuroplastic effects may depend on developmental stage and specific brain conditions. The same study found that psilocybin's effects on synaptic proteins were age-dependent and sex-dependent, with adult male mice showing more changes than females [2]. This means psilocybin is not a one-size-fits-all plasticity booster—its effects are modulated by context, age, sex, and the specific disorder.

Sources used in this answer

Related research questions